Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

NCT05817227 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT05817227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05817227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
Lead sponsor
National Cancer Institute, Naples
Phase
Observational
Overall status
Recruiting
Start date
May 19, 2022
Completion date
November 19, 2027
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer